Univariate and multivariate analyses
End points and model variables . | Univariate analysis . | Multivariate analysis . | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
HR . | OR . | 95% CI . | P . | HR . | OR . | 95% CI . | P . | |||
CHR | ||||||||||
ISAPL modeling: high vs low | — | 0.26 | 0.17 | 0.66 | .002 | — | 0.22 | 0.1 | 0.6 | .003 |
Relapse-risk group: low vs intermediate vs high | — | 0.67 | 0.39 | 0.86 | .006 | — | 0.88 | 0.45 | 1.69 | .705 |
Age at diagnosis: continuous variable | — | 0.4 | 0.2 | 0.79 | .008 | — | 0.39 | 0.2 | 0.78 | .008 |
OS | ||||||||||
ISAPL modeling: high vs low | 5.1 | — | 2.22 | 11.6 | <.001 | 6.1 | — | 2.46 | 15.4 | <.001 |
Relapse-risk group: low vs intermediate vs high | 2.86 | — | 1.75 | 4.66 | <.001 | 1.91 | — | 1.1 | 3.41 | .027 |
Age at diagnosis: continuous variable | 1.5 | — | 1.05 | 2.26 | .047 | 2.4 | — | 1.36 | 4.22 | .002 |
DFS | ||||||||||
ISAPL modeling: high vs low | 2.86 | — | 1.1 | 7.88 | .04 | 2.19 | — | 1.77 | 6.23 | .038 |
Relapse-risk group: low vs intermediate vs high | 3.25 | — | 1.51 | 7 | .003 | 2.89 | — | 1.14 | 7.27 | .024 |
Age at diagnosis: continuous variable | 1.14 | — | 0.57 | 2.28 | 0.704 | 1.14 | — | 0.45 | 2.89 | .78 |
EFS | ||||||||||
ISAPL modeling: high vs low | 3.96 | — | 2.05 | 7.65 | <.001 | 4.05 | — | 2 | 8.19 | <.001 |
Relapse-risk group: low vs intermediate vs high | 2.69 | — | 1.77 | 4.1 | <.001 | 1.93 | — | 1.17 | 3.18 | .009 |
Age at diagnosis: continuous variable | 1.34 | — | 0.93 | 1.93 | .105 | 1.77 | — | 1.1 | 2.9 | .02 |
End points and model variables . | Univariate analysis . | Multivariate analysis . | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
HR . | OR . | 95% CI . | P . | HR . | OR . | 95% CI . | P . | |||
CHR | ||||||||||
ISAPL modeling: high vs low | — | 0.26 | 0.17 | 0.66 | .002 | — | 0.22 | 0.1 | 0.6 | .003 |
Relapse-risk group: low vs intermediate vs high | — | 0.67 | 0.39 | 0.86 | .006 | — | 0.88 | 0.45 | 1.69 | .705 |
Age at diagnosis: continuous variable | — | 0.4 | 0.2 | 0.79 | .008 | — | 0.39 | 0.2 | 0.78 | .008 |
OS | ||||||||||
ISAPL modeling: high vs low | 5.1 | — | 2.22 | 11.6 | <.001 | 6.1 | — | 2.46 | 15.4 | <.001 |
Relapse-risk group: low vs intermediate vs high | 2.86 | — | 1.75 | 4.66 | <.001 | 1.91 | — | 1.1 | 3.41 | .027 |
Age at diagnosis: continuous variable | 1.5 | — | 1.05 | 2.26 | .047 | 2.4 | — | 1.36 | 4.22 | .002 |
DFS | ||||||||||
ISAPL modeling: high vs low | 2.86 | — | 1.1 | 7.88 | .04 | 2.19 | — | 1.77 | 6.23 | .038 |
Relapse-risk group: low vs intermediate vs high | 3.25 | — | 1.51 | 7 | .003 | 2.89 | — | 1.14 | 7.27 | .024 |
Age at diagnosis: continuous variable | 1.14 | — | 0.57 | 2.28 | 0.704 | 1.14 | — | 0.45 | 2.89 | .78 |
EFS | ||||||||||
ISAPL modeling: high vs low | 3.96 | — | 2.05 | 7.65 | <.001 | 4.05 | — | 2 | 8.19 | <.001 |
Relapse-risk group: low vs intermediate vs high | 2.69 | — | 1.77 | 4.1 | <.001 | 1.93 | — | 1.17 | 3.18 | .009 |
Age at diagnosis: continuous variable | 1.34 | — | 0.93 | 1.93 | .105 | 1.77 | — | 1.1 | 2.9 | .02 |
HRs and ORs >1 or <1 indicate an increased or decreased risk, respectively, of an event for the first category listed. Relapse-risk group: classification according to PETHEMA/GIMEMA criteria.6
DFS, disease-free survival; EFS, event-free survival.